Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AAPG with free AI briefings, catalyst countdowns, and dilution alerts.

AAPG · ASCENTAGE PHARMA GROUP INTERNATIONAL

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.9B Cash on Hand
17.2mo Cash Runway
Follow AAPG by email Get an email when AAPG reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AAPG, unsubscribe in one click. Privacy

📣 What AAPG Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
BTK Inhibitor CLL/SLL Phase 3 · NCT06104566 Recruiting
Cyclophosphamide,CTX CLL/SLL Phase 3 · NCT06319456 Recruiting
Olverembatinib (HQP1351) Ph+ ALL Phase 3 · NCT06051409 Recruiting
Lisaftoclax (APG-2575) CLL/SLL Phase 3 · NCT06104566 Recruiting
Investigator's choice of TKI Ph+ ALL Phase 3 · NCT06051409 Recruiting
Fludarabine CLL/SLL Phase 3 · NCT06319456 Recruiting
Omacetaxine Mepesuccinate Chronic Myeloid Leukemia, Chronic Phase Phase 2 · NCT04126681 Completed
Tucidinostat NHL, Adult Phase 1/2 · NCT05186012 Unknown
Hydroxyurea or Interferon-based therapy Chronic Myeloid Leukemia, Chronic Phase Phase 2 · NCT04126681 Completed
Nab-paclitaxel Advanced Pancreatic Cancer Phase 1/2 · NCT04643405 Terminated
Reduced-dose HHT Relapsed/Refractory Acute Myeloid Leukaemia Phase 1/2 · NCT04501120 Recruiting
standard-dose HHT Relapsed/Refractory Acute Myeloid Leukaemia Phase 1/2 · NCT04501120 Recruiting
Azacitidine AML Phase 1/2 · NCT04358393 Unknown
Alrizomadlin (APG-115) Liposarcoma Phase 1/2 · NCT04785196 Recruiting
Pelcitoclax (APG-1252) NHL, Adult Phase 1/2 · NCT05186012 Unknown
Dasminapant (APG-1387) Advanced Pancreatic Cancer Phase 1/2 · NCT04643405 Terminated

Also used in these trials (approved or third-party drugs, not AAPG's own candidates): Acalabrutinib, Rituximab, Chlorambucil, Bosutinib, Gemcitabine Hydrochloride, Toripalimab, Ibrutinib, Imatinib, Palbociclib, Pembrolizumab, Lenalidomide, Brentuximab Vedotin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AAPG holds $1.9B in cash and short-term investments and burns about $330.8M/quarter from operations, an estimated runway of 17.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 43 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AAPG files for a raise →

👥 Who Owns AAPG

Insiders 12.9% Institutions (15 holders) 0% Public and other holders 87.1%
HolderTypeShares% of sharesAs of
Dajun Yang
Chairman and CEO, Director · +318,352 options
Insider 37,742,091 10.11% 2026-05-20
Yifan Zhai
Chief Medical Officer · +699,753 options
Includes shares also reported by Dajun Yang, counted once
Insider 37,742,091 10.11% 2026-05-20
Shaomeng Wang
Director
Insider 10,053,943 2.69% 2026-03-18
Thomas J Knapp
SVP/General Counsel
Insider 362,444 0.10% 2026-03-18
Simon Dazhong Lu
Director
Insider 41,457 0.01% 2026-03-18
Marc E Lippman
Director
Insider 21,174 0.01% 2026-03-18
David Sidransky
Director
Insider 10,641 0.00% 2026-03-18
Ren Wei
Director
Insider 8,964 0.00% 2026-03-18
Changqing Ye
Director
Insider 8,964 0.00% 2026-03-18
Jin Cao
Chief Accounting Officer
Insider 5,400 0.00% 2026-03-18

Share count 373,322,192 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AAPG picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AAPG and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.